A clinical trial based at the Cleveland Clinic and the University of Nottingham, United Kingdom, is recruiting patients with relapsing-remitting multiple sclerosis (RRMS) to compare two treatment strategies, the National Multiple Sclerosis Society announced.
The DELIVER-MS study seeks to answer the question: Does early treatment with highly effective disease modifying therapies (DMT) improve the prognosis for people with multiple sclerosis (MS)? This is an area of significant controversy and no data currently exists to guide treatment choices for patients and clinicians. The study results will help guide overall treatment philosophy and will be applicable not only to a wide range of existing therapies but also to new therapies, meeting a significant unmet need in patient decision making and aiding the decision for medication approval by third parties. The Phase 4 study intends to enroll 800 participants age 18-60 across 24 centers in the U.S. and U.K. Eligibility requires patients must have taken disease-modifying therapies.
Among the sites currently recruiting participants in the U.S. are the Cleveland Clinic in Cleveland, Ohio, and Las Vegas, Ohio Health, Anschutz Medical Campus at the University of Colorado, University of Rochester, University of Virginia, Baylor College of Medicine, and the University of Wisconsin.
Funding for the DELIVER-MS study originates form the Patient-Centered Outcomes Research Institute (PCORI) and is the second PCORI-supported trial designed to help inform MS treatment
Daniel Ontaneda, MD, MSc, The Cleveland Clinic
Nikos Evangelou, MD, DPhil, University of Nottingham